Position statement – the need for efficacy evidence of edaravone

August 2019

The UK MND Clinical Studies Group, having reviewed the available evidence on the efficacy of edaravone, has agreed the following Position Statement:
The CSG believes a properly designed, randomised placebo-controlled phase 3 trial of oral edaravone is required to determine the treatment’s efficacy.  UK MND CSG – oral edaravone position statement